The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties
Open accessAbstract
The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pK(a))), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = 11 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Ertl, P., Rohde, B., & Selzer, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,084
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationGehlhaar, D. K., Verkhivker, G. M., Rejto, P. A., Sherman, C. J., Fogel, D. R., Fogel, L. J., & Freer, S. T. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90050-0 · Cited by 684
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
Kalgutkar, A., Gardner, I., Obach, R., Shaffer, C., Callegari, E., Henne, K., Mutlib, A., Dalvie, D., Lee, J., Nakai, Y., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200054021799 · Cited by 616
Waterhouse, R. (2003) · Molecular Imaging & Biology · doi:10.1016/j.mibio.2003.09.014 · Cited by 567
The impact of drug-induced QT interval prolongation on drug discovery and development
Fermini, B., & Fossa, A. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1108 · Cited by 492
Research works printed but not linked: 6
- Kalgutkar A. S., 2008, Biotechnol.: Pharm. Aspects, 9, 27
- E. C. Harrington J., 1965, Ind. Qual. Control, 21, 494
- Le Bailly de Tilleghem C., 2005, J. Chem. Inf. Model., 45, 758, 10.1021/ci049787t · doi:10.1021/ci049787t
- Mandal A., 2007, J. Chem. Inf. Model., 47, 981, 10.1021/ci600556v · doi:10.1021/ci600556v
- Deacon M., 2007, J. Pharmacol. Toxicol. Methods, 55, 238, 10.1016/j.vascn.2006.09.003 · doi:10.1016/j.vascn.2006.09.003
- Lowe C. W., 1967, Trans. Inst. Chem. Eng., 45, T3
Cited by
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Comprehensive Review in Current Developments of Imidazole-Based Medicinal Chemistry
Zhang, L., Peng, X.-M., Damu, G. L. V., Geng, R.-X., & Zhou, C.-H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21290 · Cited by 793
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Self-citationMeanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
REINVENT 2.0: An AI Tool for De Novo Drug Design
Blaschke, T., Arús-Pous, J., Chen, H., Margreitter, C., Tyrchan, C., Engkvist, O., Papadopoulos, K., & Patronov, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00915 · Cited by 496
Stepan, A. F., Subramanyam, C., Efremov, I. V., Dutra, J. K., O’Sullivan, T. J., DiRico, K. J., McDonald, W. S., Won, A., Dorff, P. H., Nolan, C. E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300094u · Cited by 468
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 375
The Blood–Brain Barrier (BBB) Score
Gupta, M., Lee, H. J., Barden, C. J., & Weaver, D. F. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01220 · Cited by 332
The significance of acid/base properties in drug discovery
Manallack, D. T., Prankerd, R. J., Yuriev, E., Oprea, T. I., & Chalmers, D. K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35348b · Cited by 329
Ion Channels as Therapeutic Targets: A Drug Discovery Perspective
Bagal, S. K., Brown, A. D., Cox, P. J., Omoto, K., Owen, R. M., Pryde, D. C., Sidders, B., Skerratt, S. E., Stevens, E. B., Storer, R. I., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3011433 · Cited by 316
The neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Classics in Chemical Neuroscience: Diazepam (Valium)
Calcaterra, N. E., & Barrow, J. C. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000056 · Cited by 281
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Leeson, P. (2012) · Nature · doi:10.1038/481455a · Cited by 266
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Peña, I., Pilar Manzano, M., Cantizani, J., Kessler, A., Alonso-Padilla, J., Bardera, A. I., Alvarez, E., Colmenarejo, G., Cotillo, I., Roquero, I., et al. (2015) · Scientific Reports · doi:10.1038/srep08771 · Cited by 260
Xiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis
Bharate, S. S., Mignani, S., & Vishwakarma, R. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01922 · Cited by 102
Link-INVENT: Generative Linker Design with Reinforcement Learning
Guo, J., Knuth, F., Margreitter, C., Janet, J. P., Papadopoulos, K., Engkvist, O., & Patronov, A. (2022) · doi:10.26434/chemrxiv-2022-qkx9f · Cited by 101
Coloring Molecules with Explainable Artificial Intelligence for Preclinical Relevance Assessment
Jiménez-Luna, J., Skalic, M., Weskamp, N., & Schneider, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01344 · Cited by 96
Brust, T. F., Alongkronrusmee, D., Soto-Velasquez, M., Baldwin, T. A., Ye, Z., Dai, M., Dessauer, C. W., van Rijn, R. M., & Watts, V. J. (2017) · Science Signaling · doi:10.1126/scisignal.aah5381 · Cited by 64
Turning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
Yin, L., Li, H., Liu, W., Yao, Z., Cheng, Z., Zhang, H., & Zou, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.003 · Cited by 54
Essential Medicinal Chemistry of Essential Medicines
Serafini, M., Cargnin, S., Massarotti, A., Pirali, T., & Genazzani, A. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00415 · Cited by 46
Kim, H. Y., Lee, J. Y., Hsieh, C.-J., Riad, A., Izzo, N. J., Catalano, S. M., Graham, T. J. A., & Mach, R. H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00191 · Cited by 16
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021) · Antioxidants · doi:10.3390/antiox10101584 · Cited by 11
“The TPSA for a molecule to penetrate the brain has to be >40 Å2 and ≤90 Å2, in agreement with the currently most accepted range [106,107].”
BackgroundTeichman, E. M., Hu, J., Lin, H.-Y., Fisher-Foye, R. L., Blando, A., Hu, X., Kaniskan, H. Ü., Montgomery, S. E., Cai, M., Parise, L. F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02972-8 · Cited by 5
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-03-25
- Volume
- 1
- Issue
- 6
- Pages
- 435-449
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2016575780
- Cited by
- 1,063
- References
- 17
- FWCI
- 38.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.